Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sarcopenia and its implications for the elderly.

R Roubenoff1

  • 1Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tuffs University, Boston, MA 02111, USA. roubenoff@hnrc.tufts.edu

European Journal of Clinical Nutrition
|October 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of Pharmacotherapies for the Treatment of Sarcopenia.

The Journal of frailty & aging·2019
Same author

Implications of ICD-10 for Sarcopenia Clinical Practice and Clinical Trials: Report by the International Conference on Frailty and Sarcopenia Research Task Force.

The Journal of frailty & aging·2018
Same author

Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force.

The Journal of frailty & aging·2016
Same author

PHARMACOLOGICAL INTERVENTIONS IN FRAILTY AND SARCOPENIA: REPORT BY THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH TASK FORCE.

The Journal of frailty & aging·2015
Same author

Cardiometabolic risks during anabolic hormone supplementation in older men.

Obesity (Silver Spring, Md.)·2013
Same author

Sarcopenia: biomarkers and imaging (International Conference on Sarcopenia research).

The journal of nutrition, health & aging·2011

Sarcopenia, the age-related loss of muscle mass and strength, accelerates with inactivity and impacts elderly health. Resistance training can treat sarcopenia, but public health strategies promoting physical activity are vital for prevention.

Area of Science:

  • Gerontology
  • Muscle physiology
  • Public health

Background:

  • Sarcopenia, characterized by age-related loss of muscle mass and strength, is a significant factor in elderly disability and mortality.
  • While a part of normal aging, sarcopenia is exacerbated by physical inactivity and affects even elite athletes.
  • The exact causes of sarcopenia remain unclear, but involve factors like motor neuron loss, reduced muscle contractility, and hormonal changes.

Purpose of the Study:

  • To review the contributing factors to sarcopenia.
  • To discuss the effectiveness of resistance training for sarcopenia.
  • To advocate for public health strategies for sarcopenia prevention.

Main Methods:

  • Literature review of sarcopenia etiology and treatment options.

Related Experiment Videos

  • Analysis of factors contributing to muscle mass and strength decline with age.
  • Evaluation of progressive resistance training as a therapeutic intervention.

    • Main Results:

    • Identified key factors in sarcopenia: motor neuron loss, decreased muscle contractility, and hormonal shifts (androgen/estrogen withdrawal, increased catabolic cytokines).
    • Progressive resistance training demonstrated safety and effectiveness in treating sarcopenia.
    • Current dissemination of effective treatments to the general population is insufficient.

    Conclusions:

    • Sarcopenia significantly impacts elderly health, increasing disability and mortality risk.
    • Progressive resistance training is a viable treatment, but broader public health initiatives are needed.
    • Promoting physical activity across all age groups is crucial to mitigate a future epidemic of age-related disability.